Aruna Bio

Aruna Bio, founded in 2016 and based in Athens, Georgia, is a private, preclinical-stage biotech focused on harnessing neural exosomes for central nervous system (CNS) disorders. The company's platform aims to overcome the significant challenge of blood-brain barrier penetration, with its lead program, AB126, demonstrating anti-inflammatory, neuroprotective, and pro-regenerative properties. With an experienced board and leadership team, Aruna Bio is building a pipeline targeting both acute and chronic neurodegenerative conditions, positioning itself in a high-need, high-value therapeutic area.

Proprietary neural cell-derived exosome platform designed to deliver therapeutic payloads across the blood-brain barrier with intrinsic neuroprotective, anti-inflammatory, and regenerative properties.

Aruna Bio competes in the crowded neurotherapeutics space, facing large pharma and biotechs exploring antibodies, gene therapy, and other modalities. It also competes within the emerging exosome field with other companies developing exosomes for drug delivery. Its key differentiation is the specific use of neural-derived exosomes, which may offer inherent CNS targeting and therapeutic activity.